However, the widespread expression of CD47 in nontumor cells poses challenges, as targeting CD47 can lead to blood toxicity, including agglutination and anemia, hindering the clinical advancement of CD47 monoclonal antibodies [33, 34]. This evidence concerns the gene CD47 and anemia.